NCI Director To Keynote Cancer Survivorship Event March 27
"Transforming Cancer Survivorship Through Research and Best Practice, provided by the University of Cincinnati Cancer Institute Survivorship Program, is scheduled for 8 a.m. to 4 p.m. Friday, March 27, at the Kingsgate Marriott Conference Center. Continuing Medical Education credit will be available.
The keynote speaker will be Julia Rowland, PhD, director, National Cancer Institute Office of Cancer Survivorship. In addition, the following will be featured speakers:
Patricia Ganz, MD, UCLA
Timothy Ahles, PhD, Memorial Sloan Kettering Cancer Center
Michael Stubblefield, MD, Memorial Sloan Kettering
Kathryn Schmitz, PhD, University of Pennsylvania
Wendy Demark-Wahnefried, PhD, RD, University of Alabama.
The event is planned to meet the needs of the following practicing health care professionals: physicians, nurses, psychologists, residents, medical students, social workers, counselors and other oncology health professionals.
For a full agenda and registration link, visit uchealth.com/events/transformingsurvivorship/. Early bird registration is available until Feb. 28. With questions, contact Pat Woellert at 513-558-9911 or
Tags
Related Stories
UC experts say proper produce washing is key defense against Cyclospora
July 17, 2026
Hamilton County Public Health reports confirmed cases of cyclosporiasis, as concerns persist. Cyclospora is a parasite that can cause a stomach illness lasting days — sometimes even weeks. University of Cincinnati medical experts say it is usually linked to contaminated water or food, often fresh produce.
UC students organize free health clinic in community
July 15, 2026
The University of Cincinnati student chapter of Remote Area Medical held its annual free health clinic July 11-12 at St. Xavier High School. Medical, dental and vision care was offered to adults and children, with no income requirements or insurance needed.
University of Cincinnati advances FLASH radiation therapy with new clinical trial
July 15, 2026
UC Cancer Center researchers led the FAST-02 trial, showing ultra-high-dose-rate FLASH proton therapy near the heart and lungs safely reduced pain from thoracic bone metastases.